Adir Orit, Sagi-Assif Orit, Meshel Tsipi, Ben-Menachem Shlomit, Pasmanik-Chor Metsada, Hoon Dave S B, Witz Isaac P, Izraely Sivan
The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Science, Tel Aviv University, Tel Aviv 6997801, Israel.
Bioinformatics Unit, The George S. Wise Faculty of Life Science, Tel Aviv University, Tel Aviv 6997801, Israel.
Cancers (Basel). 2023 Oct 13;15(20):4979. doi: 10.3390/cancers15204979.
Reciprocal signaling between melanoma brain metastatic (MBM) cells and microglia reprograms the phenotype of both interaction partners, including upregulation of the transcription factor JunB in microglia. Here, we aimed to elucidate the impact of microglial JunB upregulation on MBM progression. For molecular profiling, we employed RNA-seq and reverse-phase protein array (RPPA). To test microglial JunB functions, we generated microglia variants stably overexpressing JunB (JunB) or with downregulated levels of JunB (JunB). Melanoma-derived factors, namely leukemia inhibitory factor (LIF), controlled JunB upregulation through Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling. The expression levels of JunB in melanoma-associated microglia were heterogeneous. Flow cytometry analysis revealed the existence of basal-level JunB-expressing microglia alongside microglia highly expressing JunB. Proteomic profiling revealed a differential protein expression in JunB and JunB cells, namely the expression of microglia activation markers Iba-1 and CD150, and the immunosuppressive molecules SOCS3 and PD-L1. Functionally, JunB microglia displayed decreased migratory capacity and phagocytic activity. JunB microglia reduced melanoma proliferation and migration, while JunB microglia preserved the ability of melanoma cells to proliferate in three-dimensional co-cultures, that was abrogated by targeting leukemia inhibitory factor receptor (LIFR) in control microglia-melanoma spheroids. Altogether, these data highlight a melanoma-mediated heterogenous effect on microglial JunB expression, dictating the nature of their functional involvement in MBM progression. Targeting microglia highly expressing JunB may potentially be utilized for MBM theranostics.
黑色素瘤脑转移(MBM)细胞与小胶质细胞之间的相互信号传导会重编程两个相互作用伙伴的表型,包括小胶质细胞中转录因子JunB的上调。在此,我们旨在阐明小胶质细胞JunB上调对MBM进展的影响。为了进行分子分析,我们采用了RNA测序和反相蛋白质阵列(RPPA)。为了测试小胶质细胞JunB的功能,我们构建了稳定过表达JunB(JunB)或JunB水平下调(JunB)的小胶质细胞变体。黑色素瘤衍生因子,即白血病抑制因子(LIF),通过Janus激酶(JAK)/信号转导及转录激活因子3(STAT3)信号传导控制JunB的上调。黑色素瘤相关小胶质细胞中JunB的表达水平是异质性的。流式细胞术分析显示,除了高表达JunB的小胶质细胞外,还存在基础水平表达JunB的小胶质细胞。蛋白质组学分析揭示了JunB和JunB细胞中蛋白质表达的差异,即小胶质细胞激活标志物Iba-1和CD150以及免疫抑制分子SOCS3和PD-L1的表达。在功能上,JunB小胶质细胞的迁移能力和吞噬活性降低。JunB小胶质细胞减少了黑色素瘤的增殖和迁移,而JunB小胶质细胞保留了黑色素瘤细胞在三维共培养中增殖的能力,在对照小胶质细胞-黑色素瘤球体中靶向白血病抑制因子受体(LIFR)可消除这种能力。总之,这些数据突出了黑色素瘤介导的对小胶质细胞JunB表达的异质性影响,决定了它们在MBM进展中功能参与的性质。靶向高表达JunB的小胶质细胞可能潜在地用于MBM的诊疗。